Pharma BD Deal Intelligence
Ranks computed across 828 graded deals (Critic + Outcome Score both present).
Lilly to acquire ARMO BioSciences for $1.6B adding pegilodecakin immuno-oncology candidate.
Eli Lilly closes $1.6bn ARMO BioSciences acquisition, bolstering its immuno-oncology program through the addition of pegilodecakin, a PEGylated IL-10.
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Eli Lilly acquired ARMO BioSciences for approximately $1.6 billion ($50 per share) in an all-cash tender offer, gaining pegilodecakin (PEGylated IL-10), a Phase III immuno-oncology asset being studied across multiple solid tumor types.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Eli Lilly and Company / ARMO BioSciences Inc. (this deal) | 2018 | $1.6B | 15 |
| Eli Lilly and Company / Boehringer Ingelheim GmbH | 2011 | $444M | 89 |
| Eli Lilly and Company / Loxo Oncology, Inc. | 2019 | $8.0B | 88 |
| Eli Lilly and Company / Applied Molecular Evolution Inc. | 2003 | $400M | 88 |
| Eli Lilly and Company / ICOS Corporation | 2006 | $2.3B | 87 |
| Eli Lilly and Company / Novartis Animal Health | 2014 | $5.4B | 70 |
| Eli Lilly and Company / Incyte Corporation | 2009 | $755M | 69 |
← Browse all deals · How we score deals
More: 2018 deals · Eli Lilly and Company deals · Oncology deals